New drug combo for stomach cancer with abdominal spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer must not have the HER2 protein and must have the Claudin 18.2 marker.
- The spread to your abdominal lining must be confirmed by a laparoscopy (a small camera test).
- You must be at least 18 years old and in reasonably good health (able to do daily activities with little or no help).
- You should not have had prior immunotherapy or targeted therapy for Claudin 18.2.
- Your organs (bone marrow, liver, kidneys) need to work well enough based on blood tests.
- You cannot have cancer that has spread to other organs like the liver or lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
Hear when a new Gastric Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.